Effexor Follow-On Will Launch One Year Before XR Patent Expires, Wyeth Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Advantages of DVS-233 over venlafaxine XR include improved safety profile and no dose titration requirement, Wyeth says. DVS-233 is also in Phase III studies for the treatment of vasomotor symptoms associated with menopause. Wyeth expects to file for approval in 2006.
You may also be interested in...
Generic Effexor XR Could Hit Antidepressant Market By June 2008
Wyeth and Teva settle patent infringement suit; Teva believes it holds 180-day exclusivity for generic extended-release venlafaxine.
Generic Effexor XR Could Hit Antidepressant Market By June 2008
Wyeth and Teva settle patent infringement suit; Teva believes it holds 180-day exclusivity for generic extended-release venlafaxine.
Effexor Sales Growth Far Outpacing Antidepressant Class, Wyeth Says
Venlafaxine sales "value and volume" are growing two to three times the market rate for antidepressants, Exec VP Poussot says. Growth has been spurred by international sales; Effexor sales volume rose 2% in the U.S. during the first half of 2005.